Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 97

1.

The relationship between tyrosine kinase inhibitor therapy and overall survival in patients with non-small cell lung cancer carrying EGFR mutations.

Suzuki H, Hirashima T, Okamoto N, Yamadori T, Tamiya M, Morishita N, Shiroyama T, Otsuka T, Kitai K, Kawase I.

Chin J Cancer. 2013 Mar;32(3):136-40. doi: 10.5732/cjc.012.10160. Epub 2012 Dec 7.

2.

Clinicopathologic and molecular features of epidermal growth factor receptor T790M mutation and c-MET amplification in tyrosine kinase inhibitor-resistant Chinese non-small cell lung cancer.

Chen HJ, Mok TS, Chen ZH, Guo AL, Zhang XC, Su J, Wu YL.

Pathol Oncol Res. 2009 Dec;15(4):651-8. doi: 10.1007/s12253-009-9167-8. Epub 2009 Apr 21.

PMID:
19381876
3.

The epidermal growth factor receptor-tyrosine kinase inhibitor era has changed the causes of death of patients with advanced non-small-cell lung cancer.

Wu WS, Chen YM, Tsai CM, Shih JF, Lee YC, Perng RP, Whang-Peng J.

J Chin Med Assoc. 2013 Dec;76(12):682-5. doi: 10.1016/j.jcma.2013.08.006. Epub 2013 Sep 21.

4.

Epidermal growth factor receptor (EGFR) mutations in a series of non-small-cell lung cancer (NSCLC) patients and response rate to EGFR-specific tyrosine kinase inhibitors (TKIs).

Martínez-Navarro EM, Rebollo J, González-Manzano R, Sureda M, Evgenyeva E, Valenzuela B, Fernández FJ, Forteza J, Brugarolas A.

Clin Transl Oncol. 2011 Nov;13(11):812-8. doi: 10.1007/s12094-011-0739-1.

PMID:
22082647
5.

[EGFR mutations in patients with advanced NSCLC].

Fiala O, Pešek M, Fínek J, Brůha F, Bortlíček Z, Krejčí J, Benešová L, Minárik M.

Klin Onkol. 2012;25(4):267-73. Czech.

PMID:
22920167
6.

Different treatment orders achieved similar clinical results: a retrospective study for retreatment of epidermal growth factor receptor tyrosine kinase inhibitors in 120 patients with non-small-cell lung cancer.

Tang C, Gao H, Li X, Liu Y, Li J, Qin H, Wang W, Qu L, An J, Yang S, Liu X.

J Cancer Res Clin Oncol. 2014 Mar;140(3):427-33. doi: 10.1007/s00432-014-1582-x. Epub 2014 Jan 9.

PMID:
24401995
7.

Mutation abundance affects the efficacy of EGFR tyrosine kinase inhibitor readministration in non-small-cell lung cancer with acquired resistance.

Zhao ZR, Wang JF, Lin YB, Wang F, Fu S, Zhang SL, Su XD, Jiang L, Zhang YG, Shao JY, Long H.

Med Oncol. 2014 Jan;31(1):810. doi: 10.1007/s12032-013-0810-6. Epub 2013 Dec 14.

PMID:
24338271
8.

Relative abundance of EGFR mutations predicts benefit from gefitinib treatment for advanced non-small-cell lung cancer.

Zhou Q, Zhang XC, Chen ZH, Yin XL, Yang JJ, Xu CR, Yan HH, Chen HJ, Su J, Zhong WZ, Yang XN, An SJ, Wang BC, Huang YS, Wang Z, Wu YL.

J Clin Oncol. 2011 Aug 20;29(24):3316-21. doi: 10.1200/JCO.2010.33.3757. Epub 2011 Jul 25.

PMID:
21788562
9.

[Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].

Li J, Qu L, Wei X, Gao H, Wang W, Qin H, Tang C, Guo W, Wang H, Liu X.

Zhongguo Fei Ai Za Zhi. 2012 May;15(5):299-304. doi: 10.3779/j.issn.1009-3419.2012.05.09. Chinese.

10.

The impact of initial gefitinib or erlotinib versus chemotherapy on central nervous system progression in advanced non-small cell lung cancer with EGFR mutations.

Heon S, Yeap BY, Lindeman NI, Joshi VA, Butaney M, Britt GJ, Costa DB, Rabin MS, Jackman DM, Johnson BE.

Clin Cancer Res. 2012 Aug 15;18(16):4406-14. doi: 10.1158/1078-0432.CCR-12-0357. Epub 2012 Jun 25.

11.

Retreatment with erlotinib: Regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatment.

Becker A, Crombag L, Heideman DA, Thunnissen FB, van Wijk AW, Postmus PE, Smit EF.

Eur J Cancer. 2011 Nov;47(17):2603-6. doi: 10.1016/j.ejca.2011.06.046. Epub 2011 Jul 23.

PMID:
21784628
12.

Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) are effective for leptomeningeal metastasis from non-small cell lung cancer patients with sensitive EGFR mutation or other predictive factors of good response for EGFR TKI.

Yi HG, Kim HJ, Kim YJ, Han SW, Oh DY, Lee SH, Kim DW, Im SA, Kim TY, Kim CS, Heo DS, Bang YJ.

Lung Cancer. 2009 Jul;65(1):80-4. doi: 10.1016/j.lungcan.2008.10.016. Epub 2008 Dec 6.

PMID:
19059670
13.

First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.

Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Jänne PA, Joshi VA, McCollum D, Evans TL, Muzikansky A, Kuhlmann GL, Han M, Goldberg JS, Settleman J, Iafrate AJ, Engelman JA, Haber DA, Johnson BE, Lynch TJ.

J Clin Oncol. 2008 May 20;26(15):2442-9. doi: 10.1200/JCO.2007.14.8494. Epub 2008 May 5. Erratum in: J Clin Oncol. 2008 Jul 10;26(20):3472.

PMID:
18458038
14.

Real world impact of epidermal growth factor receptor mutation status on treatment patterns in patients with non-small cell lung cancer.

Sun JM, Rampal S, Lee G, Lee J, Choi YL, Parasuraman B, Guallar E, Cho J, Shim YM.

Lung Cancer. 2013 May;80(2):191-6. doi: 10.1016/j.lungcan.2013.01.009. Epub 2013 Feb 4.

PMID:
23384673
15.

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.

Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, Harris PL, Haserlat SM, Supko JG, Haluska FG, Louis DN, Christiani DC, Settleman J, Haber DA.

N Engl J Med. 2004 May 20;350(21):2129-39. Epub 2004 Apr 29.

16.

Efficacy of tyrosine kinase inhibitors in routine clinical practice: epidermal growth factor mutations and their implications.

Ovcaricek T, Cufer T, Kern I, Sodja E, Sadikov A.

J Cancer Res Ther. 2013 Apr-Jun;9(2):261-6. doi: 10.4103/0973-1482.113379.

17.

Prognostic value of acquired resistance-related molecules in Japanese patients with NSCLC treated with an EGFR-TKI.

Uramoto H, Yamada T, Yano S, Kondo N, Hasegawa S, Tanaka F.

Anticancer Res. 2012 Sep;32(9):3785-90.

PMID:
22993320
18.

Rebiopsy of non-small cell lung cancer patients with acquired resistance to epidermal growth factor receptor-tyrosine kinase inhibitor: Comparison between T790M mutation-positive and mutation-negative populations.

Hata A, Katakami N, Yoshioka H, Takeshita J, Tanaka K, Nanjo S, Fujita S, Kaji R, Imai Y, Monden K, Matsumoto T, Nagata K, Otsuka K, Tachikawa R, Tomii K, Kunimasa K, Iwasaku M, Nishiyama A, Ishida T, Nishimura Y.

Cancer. 2013 Dec 15;119(24):4325-32. doi: 10.1002/cncr.28364. Epub 2013 Sep 16.

19.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
20.

Efficacy of epidermal growth factor receptor tyrosine kinase inhibitors for brain metastasis in non-small cell lung cancer patients harboring either exon 19 or 21 mutation.

Park SJ, Kim HT, Lee DH, Kim KP, Kim SW, Suh C, Lee JS.

Lung Cancer. 2012 Sep;77(3):556-60. doi: 10.1016/j.lungcan.2012.05.092. Epub 2012 Jun 5.

PMID:
22677429

Supplemental Content

Support Center